The Chemical and Biological Properties of PAF Agonists, Antagonists, and Biosynthetic Inhibitors

  • T. Y. Shen
  • San-Bao Hwang
  • Thomas W. Doebber
  • James C. Robbins


As PAF was being characterized as a highly potent lipid mediator of inflammation and anaphylaxis, its unusual structure stimulated considerable interest in the investigation of various structural analogs, initially to define the structure requirement for its biological actions, and later to explore the possibility of dissociating its cardiovascular, pulmonary, and renal activities. More recently, the possible existence of multimolecular species of PAF-like molecules in vivo is also being investigated.


Platelet Activate Factor Rabbit Platelet Soluble Immune Complex Phospholipid Analog Rabbit Platelet Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson, R. C., and Nabinger, R. C, 1983, Synthesis of a novel platelet activating factor congener from diacetone glucose, Tetrahedron Letters 24:2741–2744.CrossRefGoogle Scholar
  2. Ardlie, N. G., Packham, M. A., and Mustard, J. F., 1970, Adenosine diphosphate induced platelet aggregation in suspensions of washed rabbit platelets, Br. J. Haematol. 19:7–17.PubMedCrossRefGoogle Scholar
  3. Baranes, J., Clostre, F., and Braquet, P., 1985, The effects of PAF-Acether on the cardiovascular system and their inhibition by a new highly specific receptor antagonist BN52021, Int. J. Immu-nopharmacol. 7:385.Google Scholar
  4. Benveniste, J., Tence, M., Varenne, P., Bidault, J., Boullet, C., and Polonsky, J., 1979, Semi-synthesis and proposed structure of platelet-activating factor (PAF)-PAF-acether an alkyl ether analog of lysophosphatidylcholine, Comptes rendus hebdomadaires des seances de L Academie des sciences serie D 289:1037–1040.Google Scholar
  5. Benveniste, J., Chignard, M., Le Couedic, J. P., and Vargaftig, B. B., 1982, Biosynthesis of platelet-activating factor (PAF-acether). II. Involvement of phospholipase A2 in the formation of PAF-acether and lyso-PAF-acether from rabbit platelets, Thrombosis Res. 25:375–385.CrossRefGoogle Scholar
  6. Biftu, T., Gamble, N. F., Chabala, J. C., Dallob, A., Doebber, T., Dougherty, H. W., Hwang, S. B., and Shen, T. Y., 1986, L-653,150, A dual inhibitor of 5-lipoxygenase and platelet activating factor, in: Advances in Prostaglandin, Thromboxane, and Leukotriene Research ,(in press).Google Scholar
  7. Biftu, T., Gamble, N. F., Doebber, T., Hwang, S. B., Shen, T. Y., Snyder, J., Springer, J. P., and Stevenson, R., 1986, Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists, J. Med. Chem. 23:1917–1921.CrossRefGoogle Scholar
  8. Blank, M. L., Snyder, F., Byers, L. W., Brooks, B., and Muirhead, E. E., 1979, Antihypersensitive activity of an alkyl ether analog of phosphatidylcholine, Biochem. Biophys. Res. Comm. 90:1194–1200.PubMedCrossRefGoogle Scholar
  9. Blank, M. L., Cress, E. A., Lee, T.-C., Malone, B., Surles, J. R., Piantadosi, C., Hajdu, J., and Snyder, F., 1982, Structural features of platelet activating factor (l-alkyl-2-acetyl-sn-glycero-3-phosphocholine) required for hypotensive and platelet serotonin responses, Res. Commun. Chem. Pathol. Pharmacol. 38:3–20.PubMedGoogle Scholar
  10. Bonnett, J., Loiseau, A. M., Orvoea, M., and Bessia, P., 1981, Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes, in: Pharmacology of Inflammation and Allergy: Lipids and Cells (F. Russo-Marie, B. Vargaftig, and J. Benveniste, eds.), Elsevier, Amsterdam, pp. 111–118.Google Scholar
  11. Braquet, P., 1985, BN52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists, Prostaglandins 30:687.CrossRefGoogle Scholar
  12. Buxton, D. B., Hanahan, D. J., and Olson, M. S., 1984, Stimulation of glycogenosis and platelet-activating factor production by heat-aggregated immunoglobulin G in the perfused rat liver. J. Biol. Chem. 259:13758–13761.PubMedGoogle Scholar
  13. Camussi, G., Tetta, C., Segoloni, G., Deregibus, M. C., and Bussolino, F., 1981a, Neutropenia induced by platelet-activating factor (PAF-acether), released from neutrophils-The inhibitory effect of prostacylin, Agents Actions 11:550–553.Google Scholar
  14. Camussi, G., Tetta, C., Bussolino, F., Caligaris Cappio, F., Coda, R., Masera, C., and Segoloni, G., 1981b, Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation, Int. Arch. Allergy Appl. Immun. 64:25–41.CrossRefGoogle Scholar
  15. Casals-Stenzel, J., 1985, The inhibitory activity of brotizolam and related compounds on platelet activating factor induced effects in vitro and in vivo in: New Horizons in Platelet Activating Factor Research (M. L. Lee and C.M. Winslow, eds.), Wiley, New York, p. 38.Google Scholar
  16. Casals-Stenzel, J., Muacevic, G., Heuer, H., and Weber, K. H., 1986, Inhibition of platelet activating factor (PAF) induced effects in vitro and in vivo by WEB 2086, a new and specific PAF antagonist. Second International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids ,Gatlinburg, Tennessee, October, 1986, p. 107 (abstract).Google Scholar
  17. Chandrakumar, N. S., and Hadju, J., 1983, Stereospecific synthesis of ether phospholipids-preparation of l-alkyl-2-(acylamino)-2-deoxyglycerophosphorylcholines, J. Org. Chem. 48:1197–1202.CrossRefGoogle Scholar
  18. Chang, M. N., Han, G. Q., Arison, B. H., Springer, J. P., Hwang, S.-B., and Shen, T. Y., 1985, Neolignans from piper-futokadsura, Phytochem. 24:2079–2082.CrossRefGoogle Scholar
  19. Chesney, C. M., Pifer, D. D., and Huch, K. M., 1983, Alpha-adrenergic antagonists inhibit binding of platelet activating factor (PAF) to human gel filtered platelets, in: Platelet Activating Factor and Structurally Related Ether Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, pp. 177–184.Google Scholar
  20. Demopoulos, C. A., Pinckard, R. N., and Hanahan, D. J., 1979, Platelet-activating factor-evidence for l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators), J. Biol. Chem. 254:9355–9358.PubMedGoogle Scholar
  21. Dinur, D., Kantrowitz, E. R., and Hajdu, J., 1981, Reaction of Woodwards reagent K with pancreatic porcine phospholipase A2: Modifications of an essential carboxylate residue, Biochem. Biophys. Res. Commun. 100:785–792.PubMedCrossRefGoogle Scholar
  22. Disselukotter, H., Lieb, F., Oediger, H., and Wendisch, D., 1985, Synthese von phosphonoanalogen des 2-O-acetyl-1 -O-hexadecyl(octadecyl)-sn-3-glycerylphosphoryl-cholins (platelet-activating factor), Arch. Pharm. (Weinheim) 318:695–700.CrossRefGoogle Scholar
  23. Doebber, T. W., Wu, M. S., and Shen, T. Y., 1984, Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils, Biochem. Biophys. Res. Commun. 125:980–987.PubMedCrossRefGoogle Scholar
  24. Doebber, T. W., Wu, M. S., Robbins, J. C., Choy, B., Chang, M. N., and Shen, T. Y., 1985, Platelet activating factor (PAF) involvement in endotoxin induced hypotension in rats. Studies with PAF receptor antagonist kadsurenone, Biochem. Biophys. Res. Commun. 127:799–808.PubMedCrossRefGoogle Scholar
  25. Doebber, T. W., Wu, M. S., and Biftu, T., 1986, Platelet activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF-receptor antagonist L-652,731, J. Immunol. 136:4659–4668.Google Scholar
  26. Etienne, A., Hecquet, F., Spinnewyn, B., Soulard, C., Clostre, F., and Braquet, P., 1985, In vivo inhibition of plasma protein leakage and Salmonella enteritidis-mduced mortality in the rat by specific PAF-acether receptor antagonists: BN52021 and related products, Int. J. Immunophar-macol. 7:308.CrossRefGoogle Scholar
  27. Glasser, L., Somberg, L. B., and Vogler, W. R., 1984, Purging murine leukemic marrow with alkyl-lysophoslipids, Blood 64:1288–1291.Google Scholar
  28. Godfroid, J. J., Heymans, F., Michel, E., Redeuilh, C., Steiner, E., and Benveniste, J., 1980, Platelet activating factor (PAF-acether): Total synthesis of 1–0-octadecyl 2–0-acetyl-sn-glycero-3-phos-phoryl choline, FEBS Lett. 116:161.PubMedCrossRefGoogle Scholar
  29. Goetzl. E. J., Derian, C. K., Tauber, A. I., and Valone, F. H., 1980, Novel effects of l-O-hexadecyl-2-acyl-sn-glycero-3-phosphorylcholine mediators on human leukocyte function: Delineation of the specific roles of the acyl substituents. Biochem. Biophys. Res. Commun. 94:881–888.PubMedCrossRefGoogle Scholar
  30. Goldenberg, M. M., and Meuer, R. D., 1984, A pharmacologic analysis of the action of platelet-activating factor in the induction of hindpaw edema in the rats, Prostaglandins 28:271–278.PubMedCrossRefGoogle Scholar
  31. Hadvary, P., Cassal, J.-M., Hirth, G., Barner, T., and Baumgartner, H. R., 1983, Structural requirements for the activation of blood platelets by analogues of platelet-activating factor (PAF-acether), in: Platelet-Activating Factor and Structurally Related Ether-Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, p. 57.Google Scholar
  32. Hanahan, D. J., Munder, P. G., Satouchi, K., McManus, L., and Pinckard, R. N., 1981, Potent platelet stimulating activity of anantiomers of acetyl glyceryl ether phosphorylcholine and its methoxy analogues, Biochem. Biophys. Res. Commun. 99:183–188.PubMedCrossRefGoogle Scholar
  33. Harada, M., Takeuchi. M., Fukao, T., and Katagiri, K., 1971, A simple method for the quantitative extraction of dye extravasated into the skin, J. Pharm. Pharmacol. 23:218–219.PubMedCrossRefGoogle Scholar
  34. Heymans, F., Borrel, M.-C., Broquet, C., Lefort, J., and Godfroid, J.-J., 1985, Structure-activity relationship in PAF-acether. 2. rac-l-0-octadecyl-2–0-acetyl-3–0(dimethylamino)propyl]glyc-erol, J. Med. Chem. 28:1094–1096.PubMedCrossRefGoogle Scholar
  35. Hillmar, I., Muramatsu, T., and Zollinger, N., 1984, Effects of a thio analog of platelet-activating factor on platelet-aggregation and adenosine-3, 5-monophosphate concentration in hepatocyle suspensions and in platelets-a comparison with the naturally occurring compound, Hoppe-seylers, Z. Physiol. Chem. 365:33–41.CrossRefGoogle Scholar
  36. Home, W. C., and Simons, E. R., 1978, Probes of transmembrane potentials in platelets: Changes in cyanide dye fluorescence in response to aggregation stimuli, Blood 51:741–749.Google Scholar
  37. Humphrey, D. M., McManus, L. M., Satouchi, K., Hanahan, D. J., and Pinckard, R. N., 1982, Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues, Lab. Invest. 46:422–429.PubMedGoogle Scholar
  38. Hwang, S.-B., Lee, C.-S. C., Cheah, M. J., and Shen, T. Y., 1983, Specific receptor binding for 1–0-alkyl-2–0-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes, Biochemistry 22:4756–4763.PubMedCrossRefGoogle Scholar
  39. Hwang, S.-B., Cheah, M. J., Lee, C.-S. C., and Shen, T. Y., 1984, Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets, Thromb. Res. 34:519–531.PubMedCrossRefGoogle Scholar
  40. Hwang, S.-B., Lam, M.-H., and Shen, T. Y., 1985a, Specific binding sites for platelet activating factor in human lung tissues, Biochem. Biophys. Res. Commun. 128:972–979.PubMedCrossRefGoogle Scholar
  41. Hwang, S.-B., Li, C.-L., Lam, M.-H., and Shen, T. Y., 1985b, Characterization of cutaneous vascular permeability induced by platelet activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist, Lab. Invest. 52:617–630.PubMedGoogle Scholar
  42. Hwang, S.-B., Lam, M.-H., Biftu, T., Beattie, T. R., and Shen, T. Y., 1985c, T-2,5-bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran, an orally active specific and competitive receptor antagonist of platelet activating factor, J. Biol. Chem. 260:15639–15645.PubMedGoogle Scholar
  43. Hwang, S.-B., Lam, M.-H., and Shen, T. Y., 1986a, Membrane receptors for platelet activating factor (PAF) and a competitive specific PAF-receptor antagonist, kadsurenone, Adv. Inflam. Res. 11:83-95.Google Scholar
  44. Hwang, S.-B., Lam, M.-H., and Pong, S.-S., 1986b, Ionic and GTP regulation of binding of platelet-activating factor to receptors and platelet-activating factor-induced activation of GT Pase in rabbit platelet membranes, J. Biol. Chem. 261:532–537.PubMedGoogle Scholar
  45. Hwang, S.-B., Lam, M.-H., Li, C. L., and Shen, T. Y., 1986c, Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema, Eur. J. Pharmacol. 120:33–41.PubMedCrossRefGoogle Scholar
  46. Inarrea, P., Alonso, F., and Sanchez-Crespo, M., 1983, Platelet-activating factor: An affector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse, Immunopharmacology 6:7–17.PubMedCrossRefGoogle Scholar
  47. Jouvin-Marche, E., Cerrina, J., Coeffier, E., Doroux, P., and Benveniste, J., 1983, Effect of the Ca2 + antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and β-glucuronidase from human neutrophils, Eur. J. Pharmacol. 89:19–26.PubMedCrossRefGoogle Scholar
  48. Kasuya, Y., Masuda, Y., and Shigenobu, J., 1984, Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF, Can. J. Physiol. 62:457–459.CrossRefGoogle Scholar
  49. Kertscher, H.-P., and Ostermann, G., 1985, Syntheses und biologische aktivitat einiger iosmerer struk-turanaloga des plattchenaktivierenden faktors, 1985, Pharmazie 40:55–56.Google Scholar
  50. Kloprogge, E., and Akkerman, J. W. N., 1983, Binding aspects of PAF-acether to intact human platelets, in: Platelet Activating Factor and Structurally Related Ether Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, pp 153–159.Google Scholar
  51. Kornecki, E., Ehrlich, Y. H., and Lenox, R. H., 1984, Platelet-activating factor induced aggregation of human-platelets specifically inhibited by triazolobenzodiazepines, Science 226:1454–1456.PubMedCrossRefGoogle Scholar
  52. Kritikou, L. G., Moschidis, M. C., Siafaca, A., and Demopoulos, C. A., 1983, Biological activity of phosphono-, 2–0-tri-chloroacetyl, 2-O-trifluoroacetyl-analogs of l-O-acetyl-sn-glyceryl-3-phos-phorylcholine (AGEPC) and of acetylated glyceryl ether neutral derivatives, in: Platelet-Activating Factor and Structurally Related Ether-Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, p. 65.Google Scholar
  53. Lee, M. L., Frei, A., Winslow, C., and Handley, D. A., 1983, Isosteric analogs of PAF-acether: Synthesis and biological activity of l-0-octadecyl-2-deoxy-2-(2-oxopropyl)-glycero-3-phos-phorylcholine, in: Platelet-Activating Factor and Structurally Related Ether-Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, p. 49.Google Scholar
  54. Lee, M. L., Winslow, C. M., Jaeggi, C., DAries, F., Frisch, G., Farley, C., Melden, M. K., Handley, D. A., and Saunders, R. N., 1985, Inhibition of platelet activating factor: Synthesis and biological activity of SRI 63–073, a new phospholipid PAF-acether antagonist in: Is There a Case for PAF-acether Antagonists? ,Paris, June 21, 1985, Abstr. A4.Google Scholar
  55. Miyamoto, T., Ohno, H., Yano, T., Okada, T., Hamanaka, N., and Kawasaki, A., 1984, OnO-6240 A new potent antagonist of platelet activating factor, Third International Congress of Inflammation ,Paris, Sept. 3–7, 1984, Abstr. 513–9.Google Scholar
  56. Morley, J., Page, C. P., and Paul, W., 1983, Inflammatory action of platelet activating factor (PAF-acether) in guinea pig skin, Br. J. Pharmacol. 80:503–5n9.Google Scholar
  57. Morris-Natschke, S., Surles, J. R., Daniel, L. W., Berens, M. E., Madest, E. J., and Piantadosi, C., 1986, Synthesis of sulfur analogues of alkyl lysophospholipid and neoplastic cell growth inhibitory properties, J. Med. Chem. 29:2114–2117.PubMedCrossRefGoogle Scholar
  58. Nakamura, N., Miyazaki, H., Ohkawa, N., Koike, H., Sada, T., Asai, F., and Kobayashi, S., 1984, Synthesis and biological activities of bioisosteric O-carba-analogues of platelet activation factor (PAF), Chem. Pharm. Bull. 32:2452–2455.PubMedGoogle Scholar
  59. OFlaherty, J. T., Wykle, R. L., Miller, C. H., Lewis, J. C., Waite, M., Bass, P. A., McCall, C. E., and De Chatelet, L. R., 1981, l-0-Alkyl-sn-glyceryl-3-phosphorylcholines. A novel class of neutrophil stimulants, Am. J. Pathol. 103:70–79.Google Scholar
  60. Ohno, M., Fujita, K., Shiraiwa, M., Izumi, A., Kobayashi, S., Yoshiwara, H., Kudo, I., Inoue, K., and Nojima, S., 1986, Molecular design toward biologically significant compounds based on platelet activating factor: A highly selective agent as a potential antihypertensive agent, J. Med. Chem. 29:1812–1814.PubMedCrossRefGoogle Scholar
  61. Okamoto, M., Yoshida, K., Uchida, I., Kohsaka, M., and Aoki, H., 1986, Studies of platelet activating factor (PAF) antagonists from microbial products (1) Bisdethiobis(methylthio)gliotoxin and its derivatives, Chem. Pharm. Bull. 34:340–344; (2) Pharmacological studies of FR-49175 in animal models, Chem. Pharm. Bull. 34:345–348.PubMedCrossRefGoogle Scholar
  62. Ostermann, G., Brachwitz, H., and Till, U., 1984, Halo lipids 6., stimulation of human and rabbit-blood platelets by recemic halo analogs of O-alkyl-glycerophosphocholine, Biomedica Biochim. Acta 43:349–355.Google Scholar
  63. Parente, L., and Flower, R. J., 1985, Hydrocortisone and macrocortin inhibit the zymosan-induced release of lyso-PAF from rat peritoneal leukocytes, Life Sci. 36:1225–1231.PubMedCrossRefGoogle Scholar
  64. Ponpipom, M. M., Yue, B. Z., Bugianesi, R. L., Brooker, D. R., Chang, M. N., and Shen, T. Y.,1986, Total synthesis of kadsurenone and its analogs, Tetrahedron Letters 27:309–312.CrossRefGoogle Scholar
  65. Robbins, J. C., MaChoy, B. H., Lam, M. H., Ponpipom, M. M., Rupprecht, K. M., and Shen, T. Y., 1985, A synthetic phospholipid inhibitor of platelet-activating factor (PAF) biosynthesis, Fed. Proc. 44:1269.Google Scholar
  66. Sanchez-Crespo, M., Alonso, F., Inarrea, P., Alvarez, V. and Egido, J., 1982, Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet independent mechanism, Immunopharmacology 4:173–185.PubMedCrossRefGoogle Scholar
  67. Satouchi, K., Pinckard, R. N., McManus, L. M., and Hanahan, D. J., 1981, Modification of the polar head group of acetyl glyceryl ether phosphorylcholine and subsequent effects upon platelet activation, J. Biol. Chem. 256:4425–4432.PubMedGoogle Scholar
  68. Sedivy, P., Caillard, C. G., Floch, A., Folliard, F., Mondot, S., Robaut, C., and Terlain, B., 1985, 48740 R. P.: a specific PAF-acether antagonist in: Is There a Case for PAF-acether Antagonists? Paris, June 21, 1985, Abstr. A4.Google Scholar
  69. Shen, T. Y., Hwang, S.-B., Chang, M. N., Doebber, T. W., Lam, M.-H., Wu, M. S., Wang, X., Hau, G. Q., and Li, R. Z., 1985, Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): Specific inhibition of in vitro and in vivo platelet-activating factor-induced effects, Proc. Natl. Acad. Sci. USA 82:672–676.PubMedCrossRefGoogle Scholar
  70. Storme, G. A., Berdel, W. E., van Blitterswijk, W. J., Bruyneel, E. A., DeBruyne, G. K., and Mareel, M. M., 1985, Antiinvasive effect of racemic l-O-octadecyl-2-O-methyl glycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro, Cancer Res. 45:351–357.PubMedGoogle Scholar
  71. Surles, J. R., Wykle, R. L., OFlaherty, J. T., Salzer, W. L., Thomas, M. J., Snyder, F., and Piantadosi, C., 1985, Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-l-alkyl chain, J. Med. Chem. 28:73–78.PubMedCrossRefGoogle Scholar
  72. Taugen, O., and Berman, H. J., 1972, Gel filtration of blood platelets: A methodological report, Adv. Exp. Med. Biol. 34: 235–243.Google Scholar
  73. Tence, M., Coeffier, E., Lalau Keraly, C., and Broquet, C., 1983, Effect of structural analogs of PAF-acether on platelet aggregation and desensitization, in: Platelet-Activating Factor and Structurally Related Ether-Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, p. 41.Google Scholar
  74. Terashita, Z.-I., Tsushima, S., Yoshioka, Y., Nomura, H., Inada, Y. and Nishikawa, K., 1983, CV-3988-A specific antagonist of platelet activating factor (PAF), Life Sci. 32:1975–1982.PubMedCrossRefGoogle Scholar
  75. Terashita, Z.-I., Imura, Y., Nishikawa, K. and Sumida, S., 1985, Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur. J. Pharmacol. 109:257–261.PubMedCrossRefGoogle Scholar
  76. Terashita, Z., Imura, Y., Takatani, M., Tsushima, S., and Nishikawa, K., 1986, CV-6209: A highly potent platelet activating factor (PAF) antagonist. Second International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids ,Gatlinburg, Tennessee, October 1986, p. 29 (abstract).Google Scholar
  77. Touvay, C., Vilain, B., Etienne, A., Clostre, F., Drieu, K., and Braquet, P., 1985, Proof of the involvement of PAF-acether in pulmonary complex immune systems using a specific PAF-acether receptor antagonist: BN52021, Int. J. Immunopharmacol. 7:385.CrossRefGoogle Scholar
  78. Tsushima, S., Yoshioka, Y., Tanida, S., Nomura, H., Nojima, S., and Hozumi, M., 1984, Syntheses and biological activities of N-alkyl-and N-alkenylcarbamoyl phospholipids, Chem. Pharm. Bull. 32:2700–2713.PubMedCrossRefGoogle Scholar
  79. Tuffin, D. P., and Wade, P. J., 1985, Calcium channel blocking drugs: A structural lead for PAF antagonists? in:Is There a Case for PAF-acether Antagonists? Paris, June 21, 1985, Abstr. A4.Google Scholar
  80. Valone, F. H., 1983, Specific binding of AGEPC by human platelets and polymonphonuclear leukocytes, in: Platelet Activating Factor and Structurally Related Ether Lipids (J. Benveniste and B. Arnoux, eds.), Elsevier, Amsterdam, pp 161–166.Google Scholar
  81. Valone, F. H., 1985, Inhibition of PAF binding by the calcium channel blockers diltiazem and verapamil in: New Horizons in Platelet Activating Factor Research ,(M. L. Lee and C. M. Winslow, eds.), Wiley, New York, p. 34.Google Scholar
  82. Valone, F. H., Cales, E., Reinhold, V. R., and Goetzl, E. J., 1982, Specific binding of phospholipid platelet activating factor by human platelets, J. Immunol. 129:1637–1641.PubMedGoogle Scholar
  83. Valone, F. H., and Goetzl, E. J., 1983, Specific binding by human polymorphonuclear leukocytes of the immunological mediator l-0-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine, Immunology 48:141–149.PubMedGoogle Scholar
  84. Weber, K. H., Harreus, A., Stransky, W., Walther, G., Bechtel, W. D., and Casals-Stenzel, J., 1986, Structure-activity relationship of 1,4-diazepines with PAF-antagonistic activity and absence of CNS-effects. Second International Conference on Platelet-Activating Factor and Structurally Relat ed Alkyl Ether Lipids. Gatlinburg, Tennessee, October, 1986, p. 29 (abstract).Google Scholar
  85. Wedmore, C. V., and Williams, T. J., 1981, Platelet-activating factor (PAF), a secretory product of polymorphonuclear leukocytes, increases vascular permeability in rabbit skin, Br. J. Pharmacol. 74:916P-917P.Google Scholar
  86. Winslow, C. M., Vallespir, S. R., Frisch, G. E., DAries, F. J., Kowal Delilla, A., Houlihan, W. J., Parrino, V., Schmitt, G., and Saunders, R. N., 1985, A novel platelet activating factor receptor antagonist in: Is There a Case for PAF-acether Antagonists? ,Paris, June 21, 1985, Abstr. A4.Google Scholar
  87. Winslow, C. M., Gubler, H. U., DeLillo, A. K., DAries, F. J., Frisch, G. E., Tomesch, J. C., and Saunders, R. N., 1986, Inhibition of PAF-induced ulcer formation by the specific PAF receptor antagonist, SRI-63441, Second International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids ,Gatlinburg, Tennessee, October, 1986, p. 33 (abstract).Google Scholar
  88. Wissner, A., Sum, P.-E., Schaub, R. E., Kohler, C. A., and Goldstein, P. M., 1984, Analogs of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain, J. Med. Chem. 27:1174–1181.PubMedCrossRefGoogle Scholar
  89. Wissner, A., Schaub, R. E., Sum, P.-E., Kohler, C. A., and Goldstein, B. M., 1985, Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone, J. Med. Chem. 28:1181–1187.PubMedCrossRefGoogle Scholar
  90. Wykle, R. L., Malone, B., and Snyder, F., 1980, Enzymatic synthesis of l-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid, J. Biol. Chem. 255:10256–10260.PubMedGoogle Scholar
  91. Wykle, R. L., Miller, C. H., Lewis, J. C., Schmitt, J. D., Smith, J. A., Surles, J. R., Piantadosi, C., and OFlaherty, J. T., 1981, Stereospecific activity of l-0-alkyl-2–0-acetyl-sn-glycero-3-phos-phocholine and comparison of analogs in the degranulation of platelets and neutrophils, Biochem. Biophys. Res. Commun. 100:1651–1658.PubMedCrossRefGoogle Scholar
  92. Wykle, R. L., Surles, J. R., Piantadosi, C., Salzer, W. L., and OFlaherty, J. T., 1982, Platelet activating factor (l-0-alkyl-2–0-acetyl-sn-glycero-3-phosphocholine), FEBS Lett. 141:29–32.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • T. Y. Shen
    • 1
  • San-Bao Hwang
    • 1
  • Thomas W. Doebber
    • 1
  • James C. Robbins
    • 1
  1. 1.Departments of Membrane and Arthritis Research and Biochemical RegulationMerck, Sharp & Dohme Research LaboratoriesRahwayUSA

Personalised recommendations